Key result
Optimized multipoint pacing cuts 5-year cardiovascular mortality ~50% compared to standard CRT.
Why the study?
The study aimed to assess the capacity of optimized multipoint pacing over cardiac resynchronization therapy regarding clinical, functional, and echocardiographic parameters and 5-year cardiovascular disease mortality among dyssynchronous HF patients.
Does echocardiographically optimized multipoint pacing reduce 5-year cardiovascular disease mortality compared to optimized conventional cardiac resynchronization therapy in patients with dyssynchronous heart failure?
RCT (n=80)
No
Does echocardiographically optimized multipoint pacing reduce 5-year cardiovascular disease mortality compared to optimized conventional cardiac resynchronization therapy in patients with dyssynchronous heart failure?
In patients with dyssynchronous heart failure, transitioning to echocardiographically optimized multipoint pacing at 6 months significantly reduced 5-year cardiovascular mortality and improved 12-month functional and echocardiographic parameters compared to remaining on optimized conventional CRT.
Answers are grounded in this paper and cite their sources.
May support switching to optimized multipoint pacing at 6 months to lower CV mortality in dyssynchronous HF; extends single-center phase 3 CRT optimization data.
Background Cardiac resynchronization therapy (CRT) is a fundamental component in the management of advanced heart failure (HF) characterized by electrical dyssynchrony. Purpose The aim of this study is to assess the capacity of optimized multipoint pacing (MPP) over CRT, in terms of clinical, functional, and echocardiographic parameters among dyssynchronous HF patients on 5-year cardiovascular disease mortality. Methods HUMVEE was a single-center, phase-III clinical trial that enrolled 80 patients with dyssynchronous HF, under optimal medical treatment, eligible for CRT (male 77.5%, mean age 68±10 years). All patients underwent echocardiographically optimized CRT implantation and after six months allocated to either optimized MPP or remained to optimized CRT. Clinical, laboratory and echocardiographic assessment was conducted at baseline and at 6 and 12 months since baseline. Five-year survival was also assessed. Results During the 5-year follow-up, CVD mortality was 18 deaths (18/45, 40.0%) in the optimized MPP group, and 20 (20/35 57.1%) in the optimized CRT group (p log-rank = 0.035). Patients in optimized MPP group had 0.50-times lower risk of dying, compared to those who remained in optimized CRT (95%CI, [0.26, 0.95]). No significant differences were observed between baseline and 12-month follow-up measurements, in both groups. However, in the optimized MPP group, patients had better 6-minute walking distance at 12th-month of follow-up, compared to baseline evaluation, improved VTILVOT, stroke volume, LVEF, LA volume and RV strain (all p-values <0.05). Conclusions Combining MPP with optimization, both electrical and hemodynamic, seems able to reverse the long-term progression of HF among dyssynchronous HF patients.
No takes yet. Share an insight, caveat, or question.
Iliakis et al. (2026) conducted an RCT in Dyssynchronous heart failure (n=80). Optimized multipoint left ventricular pacing (MPP) vs. Optimized cardiac resynchronization therapy (CRT) was evaluated on 5-year cardiovascular disease mortality (HR 0.50, 95% CI 0.26-0.95, p=0.035). Optimized multipoint pacing reduced 5-year cardiovascular mortality compared with remaining on optimized CRT.
Synapse has enriched 10 related papers. Consider them for comparative context: